Cutress R I, Mullee M A, Royle G T, Rew D A
Breast and Endocrine Unit, Southampton University Hospitals, Southampton, UK.
Eur J Surg Oncol. 2000 Dec;26(8):747-50. doi: 10.1053/ejso.2000.0997.
In vivo labelling of human breast tumours with bromodeoxyuridine (BrdUrd) and analysis by flow cytometry (FCM) allows the labelling index (LI), S phase duration (t(s)) and the potential doubling time (t(pot)) of the tumour to be estimated.
The data for a series of tumour specimens from 75 patients with invasive breast carcinoma were reported in 1991, correlated with their lymph-node status, tumour size and grade.
This study reports the follow-up data over 10 years in respect of time to recurrence and death from the disease. There were no significant correlations between proliferation data and outcome measures. No adverse events were identified which could be attributed to the use of the halogenated pyrimidine label in vivo.
用溴脱氧尿苷（BrdUrd）对人乳腺肿瘤进行体内标记并通过流式细胞术（FCM）分析，可估算肿瘤的标记指数（LI）、S期持续时间（t(s)）和潜在倍增时间（t(pot)）。
1991年报告了一系列来自75例浸润性乳腺癌患者的肿瘤标本数据，并将其与淋巴结状态、肿瘤大小和分级相关联。
本研究报告了10年期间疾病复发时间和死亡时间的随访数据。增殖数据与预后指标之间无显著相关性。未发现可归因于体内使用卤代嘧啶标记物的不良事件。
